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Epidemiologic background
Regarding most frequent pathologies in females, the cau-
sal link between diabetes mellitus and development of
severe cardiovascular complications is well acknowledged.
In contrast, the co-incidence of the cardiovascular disease
(CVD) and breast cancer is poorly understood. This is an
extremely unlucky situation, since compared to all other
pathologies, both - CVD and breast cancer demonstrate
the highest frequency of incidence in females. Hence, the
probability to identify a female postmenopausal patient
above 55 years old diagnosed with sporadic invasive
breast cancer but CVD-free is rather low. However, an
obvious coincidence of CVD and breast cancer in peri-
and post-menopausal females, synergic co-prevention,
common diagnostic tools and multi-drug co-treatments
are currently not considered for medical services.
Current deficits in prevention, diagnosis and
treatments of a coincident breast cancer
• Worldwide 8-12 women from hundred get diseased on
breast cancer. Around 50% of DCIS (ductal carcinoma
in situ) will progress to invasive and metastasis disease
if untreated, with 20% of recurring ones despite “appro-
priate” treatments.
• Breast cancer metastatic disease (BCMD) is currently
incurable [1].
• Causative factors such as co-incidental ones underly-
ing recurrence of DCIS or progression to invasive dis-
ease are currently not known.
• 95-98% are sporadic breast cancer cases versus 2-5%
familial ones: the majority of sporadic breast cancer
cases are peri- and post-menopausal women – the
group at significantly higher risk of CVD.
• Co-morbidities in breast cancer are considered
rather from view point of psychological aspects and pal-
liative care but not as the realistic model in biomedical
research, common diagnostic tools and treatment
multimodalities.
• Consistent data do not exist to recognise co-incident
pathologies by patient profiling.
• Cost-effective healthcare promotion in breast cancer
and its common or even persistent co-morbidities such
as CVD and diabetes is not provided.
• A gap between current research performance and
clinically applicable results is dramatic.
‘Stress proteome’ targets: innovative biomedical
approaches meet personalised healthcare
Stress response is the key ability of each organism that
enables it to adapt and survive. Individual stress response
can explain the individual reactions towards similar condi-
tions and underlies the molecular (pathological) mechan-
isms of individual outcomes [2]. The minimal stress
proteome mainly consists of the following functional
groups: Nucleic acid metabolism, Molecular chaperones,
DNA damage sensing/repair and cell cycle control, Basic
transcription, DNA replication and RNA processing,
Translation regulation, protein synthesis and degradation,
Redox regulation, CoA metabolism, Energy metabolism
and ATPases/ABC transporters [3]. These functional
groups represent potential targets to be utilised for com-
plex diagnostic tools and treatments tailored to the person.
As reviewed previously [4], genotoxicity is the most fatal
consequence of any kind of stress factor, such as the most
ubiquitous emotion stress, smoking and alcohol consump-
tion, hyperhomocysteinemia, folate and taurine deficiency,
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UV and ionising irradiation, fluctuating blood glucose con-
centration (starvation and diabetes mellitus), asphyxia /
ischaemia / stroke / reperfusion, genetic syndromes such
as Down’s syndrome, and neurodegenerative diseases such
as Huntington’s, Alzheimer’s and Parkinson’s disease, and
glaucoma. Recent studies showed individual stress
responses to be well or less adapted to life situations.
Inadequate stress response can be caused by the dysfunc-
tion of red-ox control, cell cycle machinery, apoptotic/
repair mechanisms leading to severe pathologies such as
human genetic syndromes, accelerated ageing, cardiovas-
cular and neuro/degenerative diseases and cancer [4].
Multi-modal strategies by predictive, preventive
and personalised medicine
➣ Creation of gender-specific profiles for CVD-diagnos-
tics and treatments by well-funded large-scale studies
with parity of both sexes including “omics”-based blood
analysis, molecular imaging and elaboration of gender-
specific questionnaires for accurate description of pro-
dromal and acute symptoms of CVD 5.
➣ Consideration of CVD-specific sex-determinants
such as mutated maternal mitochondrial DNA that
emerges complications and fatal outcomes of CVD.
➣ Performance of large-scale population studies to
identify most frequent profiles of co-incident pathologies
for effective treatments suitable for corresponding com-
bination of co-morbidities such as depression/diabetes/
CVD/breast cancer in female patients.
➣ Creation of strictly individual treatment priorities
and regiments request personalised medical approaches
of high plasticity and new generation of multi-cocktail
drug compositions.
➣ New drug delivery systems that allow for targeted
treatments.
➣ Reasonable convergence between diagnostic and
pharmaceutical industry in development of predictive/
prognostic approaches based on new multifunctional
targets for diagnostic and treatment purposes.
➣ Besides general prevention in populations, there is
an urgent need for targeted prevention in childhood,
adolescence and adulthood as the most cost-effective
approach that requests complete reconsideration of cur-
rent diagnostic and treatment programmes offered in
healthcare systems: major CVD risk factors overweight,
obesity and diabetes type 2 are the most frequent nutri-
tional disorders in industrialised countries.
➣ Creation of new programmes in healthcare systems
for effective promotion of and financial motivation for
healthy life-style.
➣ Creation of the network among healthcare perso-
nals dedicated to the task, namely research groups in
women’s health (predictive medicine), primary
healthcare (preventive measures) and networked clini-
cians for personalised treatments in female patient
cohorts.
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